Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.46 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.44 |
| ▸ | ESRRA | P11474 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6500261 | 1.00 | EGFR (0.54) | EGFRERBB2ERBB4ERBB3ESRRA | |
| SCHEMBL6233364 | 0.82 | EGFR (0.69) | EGFRERBB2ERBB4 | |
| SCHEMBL6233371 | 0.82 | EGFR (0.69) | EGFRERBB2ERBB4 | |
| Hydrochloric Acid SCHEMBL6239229 | 0.82 | EGFR (0.49) | EGFRERBB2ERBB4ERBB3ESRRA | |
| SCHEMBL6235597 | 0.81 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL6488925 | 0.80 | EGFR (0.79) | EGFRERBB2ERBB4 | |
| SCHEMBL6481914 | 0.80 | EGFR (0.79) | EGFRERBB2ERBB4 | |
| SCHEMBL6481918 | 0.80 | EGFR (0.79) | EGFRERBB2ERBB4 | |
| SCHEMBL6498999 | 0.76 | FLT1 (0.41) | EGFRERBB2ERBB4 | |
| SCHEMBL6483578 | 0.74 | EGFR (0.60) | EGFRERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | claimed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | claimed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | EGFR 20/4885ERBB2 1/4885ERBB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.